Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Equity Ratio (2020 - 2023)

Candel Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.46 for Q3 2023.

  • For Q3 2023, Equity Ratio fell 25.0% year-over-year to 0.46; the TTM value through Sep 2023 reached 0.46, down 25.0%, while the annual FY2022 figure was 0.61, 14.58% down from the prior year.
  • Equity Ratio for Q3 2023 was 0.46 at Candel Therapeutics, down from 0.52 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.72 in Q4 2021 and bottomed at 1.4 in Q2 2021.
  • The 4-year median for Equity Ratio is 0.61 (2022), against an average of 0.31.
  • The largest annual shift saw Equity Ratio skyrocketed 216.82% in 2021 before it decreased 25.0% in 2023.
  • A 4-year view of Equity Ratio shows it stood at 0.62 in 2020, then surged by 216.82% to 0.72 in 2021, then fell by 14.58% to 0.61 in 2022, then fell by 25.12% to 0.46 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Equity Ratio are 0.46 (Q3 2023), 0.52 (Q2 2023), and 0.59 (Q1 2023).